Propargyltakriny - inhibitory acetylcholinesterasy s anti-MAO aktivitou

Nemčíková, Lenka

Charles University Faculty of Pharmacy in Hradec Králové Department of Pharmaceutical Chemistry and Pharmaceutical Analysis Student: Lenka Nemčíková Supervisor: PharmDr. Marta Kučerová, Ph.D. Title of Thesis: Propargyltacrines - acetylcholinesterase inhibitors with anti-MAO activity Alzheimer's disease (AD) is a serious neurodegenerative disorder that affects mainly aged people. Neurodegenerative disorders lead to dementia. However, dementia is not a part of normal aging. It is the result of pathologigal process. Alois Alzheimer was the first who described AD. The causes of this disease are not clear, however partial pathological mechanisms and the risk factors are known. There is no drug for casual treatment of AD. Nowadays, we can only slow down the symptoms or development of dementia by combining pharmacological and non-pharmacological techniques. Such approach could improve the quality of life of affected people. The treatment of AD involves acetylcholinesterase (AChE) inhibitors and N-methyl-D-aspartate receptor antagonist (NMDA). Donepezil, rivastigmine and galantamine belong to AChE inhibitors. Decrease in AChE activity leads to balance in acetylcholine transmission, which is disturbed in early stages of the disease. Tacrine was the first drug launched on the market for the treatment of...

guest :: login Digital Repository
		Search		Submit		Help		About